SINAY Sarl, an environmental consulting organization, provides marine and coastline environmental consulting services. It offers impact assessments, underwater acoustics, fishery science, fishing, geophysics, and geotechnical services for applications in the fields of renewable marine energies, fisheries/aquaculture, marine protected areas, oil/military, and harbors. The company was incorporated in 2007 and is based in Caen, France.
Sentryc GmbH offers software as a service software development services. Its services, include anti counterfeiting, trademark protection, copyright, product piracy, and plagiarism. The company also provides software services, such as marketplace scan, social media scan, automatic removal, documentation and reporting, and counterfeiting analysis. The company was founded in 2019 and is based in Berlin, Germany with additional offices in Barcelona, Spain and Stettin, Poland.
Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, specializing in the discovery and early development of small molecules targeting G Protein-Coupled Receptors (GPCRs). Founded in 2001, the company focuses on developing therapeutics for Central Nervous System diseases and cancer. It employs innovative technologies, including its proprietary DTect-All platform, which identifies both orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs). This platform is particularly adept at addressing challenging GPCRs, such as orphan and peptidic receptors. Additionally, Domain Therapeutics offers BioSens-All, a platform designed to explore the signaling complexity associated with GPCR activation. The company, formerly known as Faust Pharmaceuticals SA, rebranded in December 2008 to reflect its focus on GPCR-targeted therapeutics.
Tubulis GmbH, founded in 2019 and based in Munich, Germany, focuses on the research, design, and development of protein-drug conjugates by integrating proprietary technologies with disease-specific biology. The company aims to transform the therapeutic landscape by creating innovative antibody-drug conjugates (ADCs) that enhance treatment outcomes for patients. Tubulis is dedicated to identifying new protein-drug combinations for various therapeutic applications, thereby expanding the potential of ADCs in addressing unmet medical needs.
BCD Bioscience, Inc. designs and develops an oligosaccharide library and a roadmap that connects precise carbohydrate structures with their functions as prebiotics and immunomodulators to develop pharmaceutical and food ingredients. It offers a platform for creating and commercializing novel prebiotics, synbiotics, and immuno- modularity therapies for human and animal health. BCD Bioscience, Inc. was formerly known as Calyxo Biosystems, Inc. and changed its name to BCD Bioscience, Inc. in November 2019. The company was incorporated in 2019 and is based in Davis, California.
Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2016. The company specializes in the development of human microbiome-based therapeutics and biomarkers. Its platform is designed to identify gut bacteria associated with specific phenotypes, offering a high level of precision. This capability allows researchers to determine phenotypes before conducting tests on candidate bacteria using advanced in vitro and in vivo models. By focusing on the science of the microbiome, Microbiotica aims to advance the understanding and application of live bacterial therapeutics in clinical settings.
Hepster is developing digital products and markets for insurance businesses and consumers.
77Foods, incorporated in 2019 and headquartered in Saint-Ouen-sur-Seine, France, is focused on creating innovative food alternatives. The company is developing a 100% vegetable edible fat, aiming to provide various types of plant-based meats, with an initial focus on a bacon substitute. Through its commitment to plant-based products, 77Foods seeks to cater to the growing demand for sustainable and healthier food options.
HARDLOOP SARL sells sports products online. The company sells shoes, gloves, bottles, and more. HARDLOOP SARL was incorporated in 2014 and is based in Paris, France.
The company intends to use the funds to advance its arenavirus-based lead candidates towards clinical testing. They will develop the initial product candidates using its proprietary Fast Evolution platform, which will generate virus strains with optimized anti-tumoral properties. These candidates will be selected based on their ability to re-program the immune system to specifically and efficiently eliminate the malignant tumor tissue.
Axial Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system (CNS) diseases and disorders. The company leverages its microbiome discovery platform to explore the gut-brain axis, which presents opportunities for creating innovative therapies aimed at enhancing the quality of life for individuals affected by neurological conditions. Founded in 2013 and based in Waltham, Massachusetts, Axial Therapeutics aims to address significant unmet medical needs within the CNS therapeutic landscape.
Ecto develops technology at the intersection of data and biology to enable a more efficient and sustainable aquaculture industry. We collaborate with farmers to streamline production and health management by leveraging advanced molecular tools and digital technologies. To date, our solutions have enabled farmers to create 51,510,714 additional healthy servings of protein. Ecto has offices in Boston, Atlanta, and Stavanger (Norway) and serves customers all over the world. The company was founded at Harvard Innovation Labs in 2013 by Dmitry Kozachenok, MBA and James Webb, Ph.D. The company has received competitive research grants from the US National Science Foundation, US Department of Agriculture, and Innovation Norway.
CattleEye manufactures autonomous livestock monitoring system in the United States. The company offers cloud based artificial intelligence (AI) platform that interpret and analyze visual imagery of livestock. The solution identify and measures gait, mobility score, and other behavioral signs. CattleEye was founded in 2019 and is based in the United States.
CattleEye manufactures autonomous livestock monitoring system in the United States. The company offers cloud based artificial intelligence (AI) platform that interpret and analyze visual imagery of livestock. The solution identify and measures gait, mobility score, and other behavioral signs. CattleEye was founded in 2019 and is based in the United States.
Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases.
The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics.
Proteon Therapeutics’ first drug candidate (PRT-201) is in development for the improvement of blood flow following vascular surgery procedures.
The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD).
PROTEON uses precision biology for microbiome protection to improve animal and human health, increasing environmental sustainability and eliminating the unnecessary use of antibiotics. We have developed a platform to develop and deliver bacteriophages for animal health solutions. Our pipeline includes solutions to prophylactically improve performance and food safety in poultry, as well as important prevent economically important bacterial diseases in aquaculture and dairy.
Ecto develops technology at the intersection of data and biology to enable a more efficient and sustainable aquaculture industry. We collaborate with farmers to streamline production and health management by leveraging advanced molecular tools and digital technologies. To date, our solutions have enabled farmers to create 51,510,714 additional healthy servings of protein. Ecto has offices in Boston, Atlanta, and Stavanger (Norway) and serves customers all over the world. The company was founded at Harvard Innovation Labs in 2013 by Dmitry Kozachenok, MBA and James Webb, Ph.D. The company has received competitive research grants from the US National Science Foundation, US Department of Agriculture, and Innovation Norway.
Dopavision GmbH develops a digital drug that treats myopia by targeting the neurotransmitter cascade and regulates the size of the eyeball. The company was founded in 2017 and is based in Berlin, Germany.
SportEasy is a comprehensive, easy-to-use, web and mobile app to manage amateur sports teams. It helps coaches organize their team's games and practices; communicate easily with their players; capture and analyze statistics. It offers players fun, social features to share their passion with their teammates (vote for player of the game, private forum, photo sharing...). SportEasy is available on the web, and as iPhone and Android apps. It is free, although premium paid plans will be available for teams and clubs starting Q1 2015. Launched in France in 2011, SportEasy is now available in French and English.
CytoKi Pharma ApS, a discovery stage biotech company, develops treatments for epithelial injury based diseases with an unmet medical need. The company was founded in 2019 and is based in Værløse, Denmark.
Expensya SAS is a company based in Paris, France, that specializes in developing multi-platform expense management software solutions. Founded in 2015, it provides a web application designed to streamline the management of professional expense reports. The Expensya application offers a range of features, including expense management, data export, accountant integration, archiving, email processing, mileage expense management, approval flow, cost accounting, and a statistics module. It is compatible with Android, iPhone, and Windows phone, making it accessible for users across different devices.
PEP-Therapy SAS is a biotechnology company based in Evry, France, founded in 2014. The company specializes in the development of cell penetrating and interfering peptides (CP and IP) aimed at delivering targeted therapies for severe diseases, particularly cancer. One of its key products is DPT-PEP1, a peptide designed to inhibit Caspase-9/PP2A protein interactions, effectively triggering apoptosis in cancer cells while preserving the functionality of healthy cells and other signaling pathways. By focusing on the intracellular delivery of these peptides, PEP-Therapy aims to address critical pathological mechanisms, offering a promising approach to cancer treatment.
Zipongo is a company focused on promoting healthy eating habits among individuals through personalized food recommendations. Their platform is designed for employers and health plans, providing tools and content that facilitate healthy eating both at home and in the workplace. By offering actionable data and insights on dietary impacts on overall health, Zipongo aims to enhance the well-being of employees and members while contributing to significant reductions in health-related costs. Additionally, the company provides deals on healthy food, recipes, and nutrition tips, further supporting individuals in making better food choices.
Hepster is developing digital products and markets for insurance businesses and consumers.
MedinCell S.A. is a pharmaceutical company based in Jacou, France, that specializes in developing long-acting injectable drug delivery systems using its proprietary BEPO technology. This innovative approach employs biocompatible materials to create formulations that allow for controlled and sustained release of active pharmaceutical ingredients. The company is advancing several product candidates, including mdc-IRM, a subcutaneous injection for schizophrenia currently in Phase III trials, and mdc-CWM, an intra-articular injection aimed at treating pain and inflammation. Additionally, MedinCell is exploring various formulations in research, such as mdc-WWM for contraception and mdc-ANG for central nervous system disorders. The firm focuses on optimizing the efficiency and accessibility of medical treatments across different therapeutic areas through its ongoing research and development efforts.
Iome Bio is a French company founded on discoveries from Sharpe and Kasper (Harvard) laboratories that explore microbiome-based mechanisms to develop new drugs in immuno-oncology. In particular, the company is working on new targets to overcome resistance to checkpoint inhibitors.
Opencell Software, founded in 2015, specializes in providing an open source monetization and billing platform designed to address the limitations of traditional billing systems and basic SaaS solutions. The company builds on a telco billing project initiated in 2007 by its CEO, David Meyer, to offer a flexible and efficient alternative for various industries, including telecommunications, cloud services, IoT, and utilities. With over 40 successful implementations globally, Opencell aims to deliver an agile solution that meets diverse billing needs while simplifying the complexities often associated with legacy systems.
wealthpilot GmbH, founded in 2017 and based in Munich, Germany, operates an online platform tailored for investment advisors. The company aims to democratize wealth management, allowing individuals to take control of their financial lives and achieve their financial goals. By integrating user-friendly technology with professional advisory services, wealthpilot provides a Software-as-a-Service platform that automatically analyzes and plans various types of assets. This innovative approach enables financial advisors to deliver personalized, data-driven wealth management while streamlining processes through automation, thereby enhancing their efficiency in managing both new and existing client assets.
CorWave SA is a medical device company based in Clichy, France, specializing in the development and manufacture of heart-assist pumps. Founded in 2011, CorWave focuses on innovative technologies to improve patient outcomes in advanced heart failure. Its flagship product, the CorWave Left Ventricular Assist Device (LVAD), employs a unique undulating disc wave pumping mechanism that mimics the natural pulsatile flow of the heart, significantly reducing trauma to the blood and minimizing complications such as clotting and bleeding. This technology contrasts with traditional continuous flow pumps, which lack significant pulsation. Additionally, the company offers Nemo, a minimally invasive cardiac pump designed for patients who are not candidates for LVADs, providing chronic, partial support. CorWave's devices are characterized by low power consumption and compact design, which may enable total implantability with wireless energy transfer systems.
Dermala is a biotech company specializing in the development of treatments for chronic skin diseases by leveraging human microbiome science, data analytics, and behavioral science. The company focuses on skin conditions such as acne, eczema, and skin aging by providing personalized topical and oral treatments. Its flagship product, the FOBO Kit, includes prebiotics and microbiome metabolites designed to eliminate acne-causing bacteria while fostering beneficial skin bacteria. Dermala also offers pre-medicated pads that target harmful bacteria and promote a healthier skin microbiome. To enhance treatment outcomes, the company has developed an application that utilizes data analytics, machine learning, and artificial intelligence for tracking and optimizing treatment efficacy. Established in 2014 and headquartered in San Diego, California, Dermala sells its products directly through its website.
Animab BV, a biotechnology company, develops monoclonal antibodies for livestock. It develops mimic secretory IgA, a type of natural antibody passed through colostrum and milk to protect nursing animals. The company will help swine producers with antibiotics for the control of gastrointestinal pathogens. Animab BV was incorporated in 2020 and is based in Ghent, Belgium.
Federation Bio is pioneering new platforms that target diseases in which the human microbiome can play a curative role. The company's microbial therapy leverages naturally occurring or engineered bacteria along with a diverse community of supportive bacteria to drive engraftment and durable therapeutic responses. This approach has potential in a wide range of human conditions, from metabolic disorders and cholestatic diseases to cancer and autoimmune conditions.
LARQ, Inc. manufactures and sells self-cleaning water bottles and water purification systems. The company’s bottles use UV-C LED light to eliminate bio-contaminants from water and bottle. It sells its bottles online. The company was founded in 2017 and is based in Foster City, California.
Galecto, Inc. develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company, founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
Siolta Therapeutics is a developer of human microbiome therapeutics intended to prevent and treat inflammatory diseases. The company leverages its deep knowledge of the developing gut microbiome and its role in promoting immune tolerance to develop targeted microbial therapeutics and companion diagnostics for the prevention and treatment of inflammatory diseases, enabling medical researchers to harness information from human microbiome studies to design next-generation microbial therapeutics to prevent inflammatory processes.
Since late 2015, they have dedicated ourselves to bring to the market an intelligent thermal technology that knows exactly how and when to keep people warm. The three Clim8 co-founders saw a tremendous need to create an ingredient brand – Clim8 – that would combine both Textile and Digital industries. While until now most of intelligent wearables were able to track user’s activities, Clim8 provides a technology that monitors, analyzes, activates and regulates accordingly to the user’s specific needs.
Tubulis GmbH, founded in 2019 and based in Munich, Germany, focuses on the research, design, and development of protein-drug conjugates by integrating proprietary technologies with disease-specific biology. The company aims to transform the therapeutic landscape by creating innovative antibody-drug conjugates (ADCs) that enhance treatment outcomes for patients. Tubulis is dedicated to identifying new protein-drug combinations for various therapeutic applications, thereby expanding the potential of ADCs in addressing unmet medical needs.
Citryll is a private pharmaceutical company that develops pharmaceutical drugs used to treat autoimmune and other human diseases. The company offers formation, function, and clearance of NETs downstream of the protein citrullination pathway catalyzed by Peptidylarginine Deiminase (PAD) enzymes that enable doctors to help in the treatment of lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis.
Citryll was established in 2015 and is headquartered in Oss, The Netherlands.
Enterome SA is a biotechnology company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, it specializes in disease management solutions that leverage its understanding of the gut microbiome. The company focuses on developing biomarkers, companion diagnostics, and therapeutics aimed at treating various microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. Enterome's innovative approach involves identifying bioactive molecules differentially expressed by the gut microbiome, which are crucial for regulating human physiology and immune responses. The company has established a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts. By integrating its expertise in the gut microbiome with therapeutic development, Enterome aims to create targeted solutions for complex health challenges.
TransferGo Ltd. is a London-based payment service provider, established in 2012, that specializes in international money transfers. The company caters primarily to migrant workers, allowing them to send money to their relatives without incurring high bank fees. Operating under a digital account-to-account model, TransferGo offers a cost-effective alternative to traditional banks and cash bureaus, often ensuring same-day delivery of funds to the designated recipient. As a licensed payment institution regulated by the Financial Conduct Authority, TransferGo is recognized for its secure financial transactions. The company charges a fixed fee for transfers, along with a currency conversion fee ranging from 0.6% to 1.5% per transaction, making it an attractive option for both personal and commercial money transfers.
Saagie is leading the way in big data analytics by providing DataOps Orchestration that accelerates and operationalizes analytic projects. Their mission is to unify people, process and technology enabling organizations to deliver projects from raw data to production in weeks. Saagie delivers unmatched time-to-value, is “open by design” with isolated containers, strong network engineering as well as transparent security and governance bringing trust, privacy, audit and traceability to analytic projects. Saagie includes best-in-class integration with open source and commercial technologies to support today’s Big Data/AI and analytic use cases enabling global companies to realize value from their data intensive initiatives. Ultimately, Saagie provides a Plug and Play Orchestrator for DataOps that accelerates the distribution of Artificial Intelligence (AI) and Big Data to give companies a competitive advantage across industries.
MycoTechnology utilizes fungi-based food-processing platforms to transform the flavor and value of agricultural products. The platform can be used to solve a variety of challenges faced by the food, beverage, and flavor industries. MycoTechnology has released ClearTaste, an all-natural, GMO-free, organic bitter blocker that is Kosher and Halal certified. ClearTaste improves the flavor of various agricultural products. MycoTechnology also engages in fermenting agricultural products with strains of gourmet fungi. The company offers myceliated chocolate as well as robusta and arabica coffee beans. It develops and licenses technology to the industry to naturally improve the flavor of robusta and arabica coffee. The company was incorporated in 2013 and is based in Aurora, Colorado.
ViroVet NV develops virus control solutions for the livestock industry. It offers antiviral drugs for the control and treatment of respiratory diseases of cattle and swine. The company also offers modified live virus vaccines for endemic and epizootic viral livestock diseases. ViroVet NV was founded in 2015 and is based in Leuven, Belgium.
BCD Bioscience, Inc. designs and develops an oligosaccharide library and a roadmap that connects precise carbohydrate structures with their functions as prebiotics and immunomodulators to develop pharmaceutical and food ingredients. It offers a platform for creating and commercializing novel prebiotics, synbiotics, and immuno- modularity therapies for human and animal health. BCD Bioscience, Inc. was formerly known as Calyxo Biosystems, Inc. and changed its name to BCD Bioscience, Inc. in November 2019. The company was incorporated in 2019 and is based in Davis, California.
Your Personal Robot Cameraman for INDOOR and OUTDOOR shooting.
Scipio Bioscience SAS is a biotechnology company based in Paris, France, specializing in the development and manufacture of benchtop kits designed for sample preparation in single-cell studies. Founded in 2017, the company offers innovative solutions that facilitate sequencing applications in both clinical and basic research, with a particular focus on transcriptomics. Their products enable single-cell barcoding in a test tube format, streamlining the process for researchers engaged in advanced biological studies.
Novobind Livestock Therapeutics Inc. operates as an integrated animal health company that utilizes biologics to target and neutralize pathogens affecting producers and food safety. The company was incorporated in 2012 and is based in Vancouver, Canada.
MaaT Pharma, SA, operates as a biotechnology company. It develops therapies to treat diseases related to gut microbiota imbalance. It also develops a series of microbiome-based drugs which targets mortality and comorbidities associated with blood cancer treatment. The company was founded in 2014 and is based in Lyon, France.
HARDLOOP SARL sells sports products online. The company sells shoes, gloves, bottles, and more. HARDLOOP SARL was incorporated in 2014 and is based in Paris, France.
HARDLOOP SARL sells sports products online. The company sells shoes, gloves, bottles, and more. HARDLOOP SARL was incorporated in 2014 and is based in Paris, France.
The company TIBOT technologies was born in May 2016: its objective, to develop solutions which facilitate the daily life of poultry farming. In 2015, Lætitia and Benoît called on the services of Cimtech, a design office in mechatronics located near Rennes (35), to assess the feasibility of a robot for poultry farming that could bring more comfort and profitability to their daily work.
FeetMe SAS, based in Paris, France, specializes in developing advanced insoles designed to monitor foot pressure in real time, particularly for diabetic patients. Founded in 2013, the company utilizes embedded pressure sensors in its insoles to create detailed pressure maps, enabling both patients and healthcare providers to detect changes in plantar pressure. This innovative technology addresses the significant global issue of mobility disorders, affecting approximately 100 million individuals. FeetMe's primary product, the FeetMe Monitor, combines connected insoles with mobile software to assess gait parameters and variability in real-life situations through smart algorithms and wireless connectivity. The company's solutions are marketed to pharmaceutical firms for clinical trials, rehabilitation centers for mobility assessments, and directly to patients for home rehabilitation, aiming to enhance therapeutic and rehabilitation evaluations.
JobTeaser SARL operates a recruitment platform designed for students and recent graduates, facilitating access to internships, job placements, and entry-level positions. Established in 2008 and based in Paris, France, the platform offers over 5,000 job opportunities and provides multimedia resources such as videos showcasing various companies and career paths. Additionally, JobTeaser offers career guidance, advice on job selection, and opportunities for users to engage directly with recruiters. The platform aims to enhance the job search experience for young professionals by combining practical job listings with valuable support and insights into potential career trajectories.
LNC Therapeutics is developing gut microbiota directed drugs to target obesity and associated cardiometabolic diseases. All projects encompass fundamental research, preclinical studies and clinical trials. Backed by leading venture capital investors, such as Seventure Partners (with the microbiome dedicated vehicle Health for Life Capital) and Family Offices, the company cultivates worldwide collaborations with renowned medical experts to ensure the highest level of standards in the development of innovative drugs. With a total of € 16.5 million raised so far including € 1.5 million grants from French BPI and Aquitaine Region, LNC Therapeutics will pursue its research programs to bring the next generation approach to treat obesity and cardiometabolic diseases.
String Bio designs sustainable industrial products security that improves worldwide food security. The company uses methane as a source of carbon for biodegradable products and introduces a sustainable protein allowing users to determine with a simple test for high-value industrial chemicals and transportation fuels, enabling companies to help meet the growing global demand for protein.
DayTwo Ltd. is a precision medicine company based in Tel Aviv-Yafo, Israel, founded in 2015. The company operates a web-based platform that leverages gut microbiome analysis to provide personalized health solutions, particularly for metabolic diseases such as diabetes, prediabetes, clinical obesity, and non-alcoholic fatty liver disease. DayTwo's innovative approach, grounded in research published in reputable scientific journals, recognizes that individuals react differently to foods, making tailored dietary recommendations essential for effective treatment. By analyzing stool samples, DayTwo creates individualized Food Prescriptions™ designed to optimize blood sugar levels, enhance energy, manage appetite, and support weight loss. Its services are delivered through a digital app, facilitated by Certified Diabetes Care and Education Specialists and Registered Dietitians, enabling users to monitor their progress and communicate with care providers. DayTwo tracks clinical outcomes such as A1C and Time In Range, offering a performance-based fee structure for users who adhere to its program.
Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, specializing in the discovery and early development of small molecules targeting G Protein-Coupled Receptors (GPCRs). Founded in 2001, the company focuses on developing therapeutics for Central Nervous System diseases and cancer. It employs innovative technologies, including its proprietary DTect-All platform, which identifies both orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs). This platform is particularly adept at addressing challenging GPCRs, such as orphan and peptidic receptors. Additionally, Domain Therapeutics offers BioSens-All, a platform designed to explore the signaling complexity associated with GPCR activation. The company, formerly known as Faust Pharmaceuticals SA, rebranded in December 2008 to reflect its focus on GPCR-targeted therapeutics.
TransferGo Ltd. is a London-based payment service provider, established in 2012, that specializes in international money transfers. The company caters primarily to migrant workers, allowing them to send money to their relatives without incurring high bank fees. Operating under a digital account-to-account model, TransferGo offers a cost-effective alternative to traditional banks and cash bureaus, often ensuring same-day delivery of funds to the designated recipient. As a licensed payment institution regulated by the Financial Conduct Authority, TransferGo is recognized for its secure financial transactions. The company charges a fixed fee for transfers, along with a currency conversion fee ranging from 0.6% to 1.5% per transaction, making it an attractive option for both personal and commercial money transfers.
LiMM Therapeutics operates as a biopharmaceutical company that harnesses the molecular cross-talk between neuronal and innate lymphoid cells. It develops products designed to preserve health and treat inflammatory, infectious, and metabolic diseases. The company is dedicated to bridging neural sensing and immunology discoveries to unlock therapeutic solutions for the benefit of patients.
Axial Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system (CNS) diseases and disorders. The company leverages its microbiome discovery platform to explore the gut-brain axis, which presents opportunities for creating innovative therapies aimed at enhancing the quality of life for individuals affected by neurological conditions. Founded in 2013 and based in Waltham, Massachusetts, Axial Therapeutics aims to address significant unmet medical needs within the CNS therapeutic landscape.
BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies that target harmful bacteria linked to various diseases. The company aims to treat conditions associated with microbiome imbalances, including skin conditions, inflammatory bowel diseases, liver disorders, and colorectal cancer. BiomX's lead product candidates include BX001, which addresses skin appearance issues, BX002 for inflammatory bowel disease, BX003 for bacteria related to progressive liver disease, and BX004 targeting chronic pulmonary infections caused by Pseudomonas aeruginosa. The company collaborates with notable institutions such as The Weizmann Institute of Science, Takeda, Keio University, JSR Corporation, and Janssen Research & Development to advance its microbiome-based therapeutic products. Founded in 2015, BiomX leverages innovative research from its scientific collaborators to develop novel therapeutics aimed at improving health outcomes.
Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing of rationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.
It was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Expensya SAS is a company based in Paris, France, that specializes in developing multi-platform expense management software solutions. Founded in 2015, it provides a web application designed to streamline the management of professional expense reports. The Expensya application offers a range of features, including expense management, data export, accountant integration, archiving, email processing, mileage expense management, approval flow, cost accounting, and a statistics module. It is compatible with Android, iPhone, and Windows phone, making it accessible for users across different devices.
Presto Engineering, Inc. is a provider of outsourced development operations for semiconductor and Internet of Things (IoT) device companies. Founded in 2006 and headquartered in San Jose, California, the company specializes in a wide array of services including turnkey IoT components, radio-frequency (RF) and mixed-signal solutions, wafer fabrication, and backend processing. It also offers comprehensive testing and qualification services, encompassing product debugging, reliability analysis, and failure analysis. Additionally, Presto Engineering delivers supply chain solutions and various lab services such as electrostatic discharge testing and compliance testing for high-definition multimedia interfaces. With offices in France, Thailand, and Taiwan, Presto Engineering serves a diverse client base, helping them minimize overhead, reduce risk, and accelerate time-to-market in the semiconductor industry.
Safe and simple booking of holiday rental properties
Galecto, Inc. develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company, founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2016. The company specializes in the development of human microbiome-based therapeutics and biomarkers. Its platform is designed to identify gut bacteria associated with specific phenotypes, offering a high level of precision. This capability allows researchers to determine phenotypes before conducting tests on candidate bacteria using advanced in vitro and in vivo models. By focusing on the science of the microbiome, Microbiotica aims to advance the understanding and application of live bacterial therapeutics in clinical settings.
VEACT GmbH, founded in 2010 and based in Munich, Germany, specializes in providing software-as-a-service solutions for after-sales marketing in the automotive sector. The company develops a platform that digitizes marketing processes, leveraging self-learning technology and extensive industry expertise. VEACT integrates various data sources, including invoices, service histories, satisfaction surveys, and campaign data, to create comprehensive customer profiles. This approach aims to facilitate predictive customer intelligence, allowing car dealerships and manufacturers to enhance their marketing and sales efficiency. By utilizing these insights, clients benefit from reduced process costs, improved customer loyalty, and increased revenues.
Launchmetrics is a Brand Performance Cloud that arms fashion, luxury, and beauty executives with the tools and data to create inspiring, shareworthy, and measurable experiences to attract today’s modern consumer. With over a decade of experience, the company develops software that helps companies in the fashion, luxury, and cosmetics sectors, helping them grow their businesses and streamline their processes. It is the most essential and trusted technology in the industry, yielding an unrivaled market penetration to 50% of the top 100 luxury brands worldwide in addition to fashion, beauty, and retailer giants such as Dior, Fendi, TopShop, Shiseido, NET-A-PORTER, Adidas, and more. Founded in NYC, with operating headquarters in Paris, Launchmetrics has employees in eight markets and support in five languages. The company works with over 1,000 brands as well as partners like IMG, the Council of Fashion Designers of America, the British Fashion Council, Camera Nazionale della Moda Italiana, Pitti Immagine, and Google, to accelerate their business and build lasting exposure.
Private Equity Round in 2018
MDoloris Medical Systems SAS specializes in the development and manufacturing of medical devices aimed at monitoring and alleviating patient pain. The company offers the Analgesia Nociception Index (ANI) monitors, which provide direct measurements of the autonomic nervous system's activity, along with ANI sensors and PhysioDoloris monitors. These devices are utilized in various settings, including general anesthesia, post-surgical wards, intensive care units, obstetrics, and neonatal care. The technology is particularly valuable for non-communicating patients, enabling healthcare providers to assess and manage pain effectively. Founded in 2010 and based in Loos, France, MDoloris also provides after-sales services to support its clients.
Izicap SAS, founded in 2013 and based in Nice, France, specializes in payment processing solutions for merchants and electronic banking partners. The company offers an innovative digital marketing platform that transforms payment cards into loyalty cards, enabling small merchants and acquirers to effectively engage customers. By capturing and analyzing payment card data, Izicap provides valuable insights through its dashboard and facilitates targeted digital marketing campaigns. Its services include automated loyalty programs and promotional campaigns via email and messaging, catering to a diverse clientele that includes restaurant owners, chain stores, and franchises. Izicap's solutions are designed to enhance customer loyalty and increase spending among end customers.
LiMM Therapeutics operates as a biopharmaceutical company that harnesses the molecular cross-talk between neuronal and innate lymphoid cells. It develops products designed to preserve health and treat inflammatory, infectious, and metabolic diseases. The company is dedicated to bridging neural sensing and immunology discoveries to unlock therapeutic solutions for the benefit of patients.
IDnow is a technology company based in Munich, Germany, specializing in identity verification services through its Identity-as-a-Service platform. Established in 2014, the company employs advanced machine-learning technology to provide real-time identity verification that ensures legal security across Europe and maintains high data security standards. IDnow's solutions enable businesses to conduct customer identification and contract signings online without the need for additional hardware, making it particularly appealing to sectors such as banking, telecommunications, and fintech. The company's clientele includes notable firms like Commerzbank, UBS, Sixt neuwagen, Telefónica, and N26, highlighting its reputation in the industry.
Indexima is a company based in Montrouge, France, founded in 2016, that specializes in developing a data hub platform aimed at enhancing analytics for data-driven organizations. The platform facilitates immediate access to data for business analysts using popular analytics tools such as Tableau, Microsoft Power BI, Qlik, and others. By leveraging advanced technologies, including artificial intelligence and innovative indexing methods, Indexima enables rapid responses to analytical queries, regardless of the data volume involved. This capability allows companies to streamline their access to commercial, marketing, financial, and technical data, ultimately simplifying and accelerating their data analysis and science processes.
A-Mansia Biotech is a developer of products based on the properties of the Akkermansia muciniphila (A. muciniphila) bacterium. The company's nutritional supplement based on a gut bacterium called Akkermansia, the population of microorganisms housed in the gastrointestinal tract. A. muciniphila is located in the mucus layer covering the intestinal epithelium, which allows the bacterium to establish a close cross-talk with the host.
Fire1, based in Dublin, Ireland, is dedicated to developing innovative therapeutic devices aimed at enhancing the lives of heart failure patients. The company has created a remote monitoring system that allows healthcare providers to access real-time patient data and insights. This technology facilitates the early detection of complications associated with heart failure, enabling proactive interventions that can lead to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to address critical challenges in heart failure management and contribute to better healthcare solutions.
Zipongo is a company focused on promoting healthy eating habits among individuals through personalized food recommendations. Their platform is designed for employers and health plans, providing tools and content that facilitate healthy eating both at home and in the workplace. By offering actionable data and insights on dietary impacts on overall health, Zipongo aims to enhance the well-being of employees and members while contributing to significant reductions in health-related costs. Additionally, the company provides deals on healthy food, recipes, and nutrition tips, further supporting individuals in making better food choices.
Enterome SA is a biotechnology company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, it specializes in disease management solutions that leverage its understanding of the gut microbiome. The company focuses on developing biomarkers, companion diagnostics, and therapeutics aimed at treating various microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. Enterome's innovative approach involves identifying bioactive molecules differentially expressed by the gut microbiome, which are crucial for regulating human physiology and immune responses. The company has established a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts. By integrating its expertise in the gut microbiome with therapeutic development, Enterome aims to create targeted solutions for complex health challenges.
Siolta Therapeutics is a developer of human microbiome therapeutics intended to prevent and treat inflammatory diseases. The company leverages its deep knowledge of the developing gut microbiome and its role in promoting immune tolerance to develop targeted microbial therapeutics and companion diagnostics for the prevention and treatment of inflammatory diseases, enabling medical researchers to harness information from human microbiome studies to design next-generation microbial therapeutics to prevent inflammatory processes.
Il Etait Un Fruit is offering delicious dehydrated fruit petals. Fruits, just fruits, selected for their taste, sliced and then simply dried to preserve their nutritional value, without additives or added sugar. Fruits produced and processed in Languedoc Roussillon!
PEP-Therapy SAS is a biotechnology company based in Evry, France, founded in 2014. The company specializes in the development of cell penetrating and interfering peptides (CP and IP) aimed at delivering targeted therapies for severe diseases, particularly cancer. One of its key products is DPT-PEP1, a peptide designed to inhibit Caspase-9/PP2A protein interactions, effectively triggering apoptosis in cancer cells while preserving the functionality of healthy cells and other signaling pathways. By focusing on the intracellular delivery of these peptides, PEP-Therapy aims to address critical pathological mechanisms, offering a promising approach to cancer treatment.
Scipio Bioscience SAS is a biotechnology company based in Paris, France, specializing in the development and manufacture of benchtop kits designed for sample preparation in single-cell studies. Founded in 2017, the company offers innovative solutions that facilitate sequencing applications in both clinical and basic research, with a particular focus on transcriptomics. Their products enable single-cell barcoding in a test tube format, streamlining the process for researchers engaged in advanced biological studies.
FeetMe SAS, based in Paris, France, specializes in developing advanced insoles designed to monitor foot pressure in real time, particularly for diabetic patients. Founded in 2013, the company utilizes embedded pressure sensors in its insoles to create detailed pressure maps, enabling both patients and healthcare providers to detect changes in plantar pressure. This innovative technology addresses the significant global issue of mobility disorders, affecting approximately 100 million individuals. FeetMe's primary product, the FeetMe Monitor, combines connected insoles with mobile software to assess gait parameters and variability in real-life situations through smart algorithms and wireless connectivity. The company's solutions are marketed to pharmaceutical firms for clinical trials, rehabilitation centers for mobility assessments, and directly to patients for home rehabilitation, aiming to enhance therapeutic and rehabilitation evaluations.
LNC Therapeutics is developing gut microbiota directed drugs to target obesity and associated cardiometabolic diseases. All projects encompass fundamental research, preclinical studies and clinical trials. Backed by leading venture capital investors, such as Seventure Partners (with the microbiome dedicated vehicle Health for Life Capital) and Family Offices, the company cultivates worldwide collaborations with renowned medical experts to ensure the highest level of standards in the development of innovative drugs. With a total of € 16.5 million raised so far including € 1.5 million grants from French BPI and Aquitaine Region, LNC Therapeutics will pursue its research programs to bring the next generation approach to treat obesity and cardiometabolic diseases.
Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in developing Eligobiotics, a novel class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, Eligo Bioscience utilizes a combination of the CRISPR/Cas system and engineered phage capsids to create antibiotics aimed at treating diseases associated with the human microbiome and resistant pathogens. Their innovative approach allows for the precise eradication of virulent bacteria, addressing the growing challenge of antibiotic resistance. The potential applications of their technology extend beyond therapeutics to include areas such as cosmetics and biodefense, positioning Eligo Bioscience at the forefront of next-generation antimicrobial development.
MycoTechnology utilizes fungi-based food-processing platforms to transform the flavor and value of agricultural products. The platform can be used to solve a variety of challenges faced by the food, beverage, and flavor industries. MycoTechnology has released ClearTaste, an all-natural, GMO-free, organic bitter blocker that is Kosher and Halal certified. ClearTaste improves the flavor of various agricultural products. MycoTechnology also engages in fermenting agricultural products with strains of gourmet fungi. The company offers myceliated chocolate as well as robusta and arabica coffee beans. It develops and licenses technology to the industry to naturally improve the flavor of robusta and arabica coffee. The company was incorporated in 2013 and is based in Aurora, Colorado.
Intento Design SA specializes in developing software solutions that enhance the design and migration processes of analog and mixed-signal integrated circuits. Founded in 2015 and headquartered in Paris, France, the company offers ID-Xplore, a tool that automates circuit sizing and streamlines the analog design process, significantly reducing latency. In addition to its software, Intento Design provides services such as methodology adoption, design collaboration, and technology migration. Their innovative approach aims to address productivity challenges faced by electrical designers, particularly in industries like consumer electronics, the Internet of Things, big data, military, and medical markets. The company's work is rooted in research conducted at the Laboratoire d’Informatique de Paris 6, leading to a robust portfolio of intellectual property that supports its mission to simplify and accelerate the analog design cycle for complex systems on chip (SoCs) used in various connected applications.
Machtfit is a health wellness and fitness company, provides corporate health solutions for companies and their employees.
Anaeropharma Science, Inc., a biopharmaceutical company, engages in the development of therapeutics that target hypoxic environment in solid cancers based on i-DPS (in situ delivery and production system), a platform technology that utilizes recombinant Bifidobacterium. It provides APS001F, a solution for solid cancer; anticancer drugs in the area of immuno-oncology and an anti-ischemic drug; and FGF2, a solution for ischemia treatment. The company was founded in 2004 and is based in Chiyoda, Japan.
Push Doctor is Europe’s largest digital health brand – and began connecting patients to a smart network of thousands of UK qualified GPs in as little as 6 minutes on any device. Providing nine out of ten patients with a resolution during their digital consultation. Today the brand is evolving to encompass the widest range of medical, health, wellness and lifestyle products / services with the core goal of enabling its customers to live happier, longer lives. Push Doctor. For Health. For Life Speak to a GP online at PushDoctor.co.uk or via the iOS and Android apps anywhere in the World, seven days a week, 365 days a year, and receive diagnosis, referral letters, fit for work notes and if necessary, prescription medication.
DayTwo Ltd. is a precision medicine company based in Tel Aviv-Yafo, Israel, founded in 2015. The company operates a web-based platform that leverages gut microbiome analysis to provide personalized health solutions, particularly for metabolic diseases such as diabetes, prediabetes, clinical obesity, and non-alcoholic fatty liver disease. DayTwo's innovative approach, grounded in research published in reputable scientific journals, recognizes that individuals react differently to foods, making tailored dietary recommendations essential for effective treatment. By analyzing stool samples, DayTwo creates individualized Food Prescriptions™ designed to optimize blood sugar levels, enhance energy, manage appetite, and support weight loss. Its services are delivered through a digital app, facilitated by Certified Diabetes Care and Education Specialists and Registered Dietitians, enabling users to monitor their progress and communicate with care providers. DayTwo tracks clinical outcomes such as A1C and Time In Range, offering a performance-based fee structure for users who adhere to its program.
BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies that target harmful bacteria linked to various diseases. The company aims to treat conditions associated with microbiome imbalances, including skin conditions, inflammatory bowel diseases, liver disorders, and colorectal cancer. BiomX's lead product candidates include BX001, which addresses skin appearance issues, BX002 for inflammatory bowel disease, BX003 for bacteria related to progressive liver disease, and BX004 targeting chronic pulmonary infections caused by Pseudomonas aeruginosa. The company collaborates with notable institutions such as The Weizmann Institute of Science, Takeda, Keio University, JSR Corporation, and Janssen Research & Development to advance its microbiome-based therapeutic products. Founded in 2015, BiomX leverages innovative research from its scientific collaborators to develop novel therapeutics aimed at improving health outcomes.
Pitchy Bros Prod SAS, founded in 2013 and based in Paris, France, offers a software as a service (SaaS) solution that simplifies the video creation process. Users can select from a variety of ready-to-use templates tailored for different scenarios, such as investor pitches or product descriptions. By uploading their own text, images, logos, and videos, users can produce a personalized video in just a few minutes. Pitchy provides flexible payment options, allowing users to either purchase the video outright or subscribe to a monthly plan, which includes hosting the video on Pitchy's platform. The company utilizes Adobe After Effects to design motion graphics templates, which are accessible through its website, ensuring a streamlined production process without manual intervention.
TargEDys SAS develops mechanisms involving hormone mimetic proteins linked to microbiota for the treatment of eating disorders such as hyperphagia or anorexia. TargEDys SAS was incorporated in 2011 and is based in Rouen, France.
Business Table is the leader in corporate dining and corporate events, with more than 30,000 service providers, including 15,000 restaurants, 1,500 caterers and 14,000 hotels and locations across France. This innovative solution launched in 2012 allows companies, from large groups to SMEs, to streamline the management of meal costs through a simple, innovative and efficient booking, ordering and invoicing tool. To expand its service offering, Business Table has partnered with American Express, Concur, Edenred and AirPlus
Botfuel SAS is a Paris-based company founded in 2016 that provides a web-based platform for creating chatbots aimed at enhancing customer engagement for businesses. The platform utilizes artificial intelligence to develop modular and scalable chatbots, allowing companies to offer automated and personalized customer support through popular messaging channels. By facilitating interaction between businesses and their customers, Botfuel aims to improve customer service and drive sales, ultimately making customer support more profitable. The solutions provided by Botfuel enable businesses to engage effectively with their audiences while leveraging existing communication platforms.
SAS Chronotruck provides Chronotruck, an application that connects shippers and carriers in real time. It enables users to find trucks for shipments from carriers. The company was founded in 2014 and is based in Aubergenville, France. As of July 9, 2019, SAS Chronotruck operates as a subsidiary of GEFCO S.A..